Business
Lyell Immunopharma Announces Participation in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am
About this update from Lyell Immunopharma, Inc.
[{"type":"image","alt":"Lyell Immunopharma, Inc","displaySize":"","headline":null,"caption":"Lyell Immunopharma, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":222,"url":"https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WaBelUh.Qn.LB3sDHM_I1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMQ--/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/WaBelUh.Qn.LB3sDHM_I1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMQ--/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences:","length":362,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"text","content":"A live webcast of each fireside chat can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of each webcast will be available on the Company's website following each event.","length":223,"tagName":"p"},{"type":"text","content":"About Lyell Immunopharma, Inc.","length":30,"tagName":"p"},{"type":"text","content":"Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consiste...